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In this study we address whether there is an association be-
tween ras mutations and disease progression in malignant 
melanoma. DNA was extracted from 100 paraffin-embedded 
melanomas and sequences around the 12th, 13th and 61st 
codons of N-, H-, and K-ras were amplified using the polym-
erase chain reaction and probed for single base pair mutations 
using synthetic oligonucleotide probes. Thirty-six melano-
mas contained mutations, which in 25 cases (69%) occurred 
at the 61st codon of N-ras. The results from dot blot hybrid-
izations were confirmed by subcloning and sequencing the 
polymerase chain reaction products from two tumors. No ras 
mutations were found in Clark's level I melanomas, whereas 
19% of level II and 45% of the more advanced primary 
M alignant melanoma is an ideal model for the study of tumor biology because biopsy material is avail-able from each stage of a well-defined sequence of malignant progression [1]. Melanoma begins as an ill situ tumor limited to the epidermis possessing 
no metastatic potential. The next stage of progression is the radial 
growth phase where melanoma invades only superficially into the 
dermis and exhibits a low metastatic potential [2] . After a variable 
period the vertical growth phase begins. The vertical growth phase 
is characterized by an expansile, invasive tumor nodule that pos-
sesses high metastatic potential [1,2]. Metastatic spread is the final 
stage of melanoma progression and is associated with a poor prog-
nosis [3]. 
Ultraviolet radiation (UVR) has been causally linked to mela-
noma initiation [3 - 5] and progression [5,6]. UVR is a known mela-
nocyte mutagen [5] and induces specific mutations in cellular 
oncogenes such as p53 [7] and ras [8 ,9]. These mutations alter the 
regulation of cell growth [10,11] and contribute to the initiation 
and progression of human cancers by activating oncogenes and in-
activating tumor-suppressor genes [12,13]. Van T' Veer et al re-
ported in a study of 10 primary and 40 metastatic melanomas and 13 
melanoma cell lines that ras mutations occurred only in melanomas 
from sun-exposed skin [14] . Five of the ten primary tumors studied 
had mutated N-ras. Four of the patients with primary tumors with 
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tumors contained ras mutations (Chi squared test: p < 0.05). 
The median Breslow thickness of primary melanomas with 
ras mutations was 0.72 mm, significantly thicker than the 
0.42 mm of melanomas without mutations (Mann-Whitney 
U test, p = 0.042). Ras mutations were found more fre-
quently in primary tumors from continuously exposed skin 
(56%) than tumors from intermittently or non-sun exposed 
sites (21 %). Fifty percent of locally recurrent and 47% of 
metastatic melanomas had ras mutations. We conclude that 
ras mutations occur in a subset of melanomas from sun-ex-
posed skin as a feature of tumor progression. Key words: mis-
match hybridization/polymerase chain reaction/DNA sequellcing. 
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mutated N-ras had metastases. These metastases all contained mu-
tated N-ras. Van T' Veer et al hypothesized that UVR causes activat-
ing ras mutations in human melanocytes thus contributing to the 
development ?f ~eoplasia [14] . The authors further hypothesized 
that ras mutation III melanoma occurs as a premetastatic event [14]. 
Other studies of ras mutations in human melanoma have focused 
primarily on the genetic changes in cell lines established from meta-
static tumors [15 -19] . In these studies, the majority of mutations 
occurred at the 61st codon of N-ras [14,15,18,20]. However, these 
results may not apply to ill vivo melanomas because cell lines can 
contain ras mutations a~ an adaptation to hi vitro growth [21]. The 
r~sult.s from these studies [~4-18] may reflect the biology of cell 
hnes III culture rather than Important mutations in ill vivo melano-
mas. A few studies have also examined primary melanomas for ras 
mutations [14,15,20,22]. However, these were small studies that 
only found between one and four ras mutations in series of 15 to 37 
tumors. The investigators neither specified tumor thickness nor 
Clark's levels [14,15,20] nor whether the tumors were from sun-
exposed skin [15,20,22]. 
Utilizing a series of 100 primary and metastatic melanomas, we 
sought to determine if ras mutations occur more frequently as an 
early or lat~ event 11l melanoma progression and if they occur more 
frequently 11l melanomas from sun-exposed sites. 
MATERIALS AND METHODS 
Tumor Specimens Biopsies from 100 formalin-fixed paraffin-embedded 
melanomas at dIfferent stages of tumor progression were reviewed by Loren 
Golitz and Nigel Ball and the diagnoses confirmed. In all cases, the tumor 
was estimated to represent at least 10% of the biopsy. Ninery cases were 
taken consecutively from the Department of Pathology, University of Col-
orado Health Sciences Center and Loren Golitz's consultation files . An 
additional 10 cases were primary melanomas from the same patients from 
wluch metastatIc tumors were evaluated in the original series. DNA was 
extracted from paraffinized tissue sections using a modification of a previ-
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ously published protocol [23] . B~tween 1 and .10 S-J.lm sections were cut 
from each case adjacent to the sectIOns used for histologIC study. The number 
of sections was adjusted so that the total surface area of the sections processed 
was the same in each case. Sections were deparaffinized with two washes in 
1 ml of xylene, then dehydrated with two washes in 1 mI of absolute eth-
anol, dried in a speedvac, and resuspended in sterile distilled water. This 
suspension was then heate.d to 95°C for 10 minand thc:n ~ept at 64°C for 
4 h with vigorous vortexmg every 10 to 15 mm. SOniCation was used to 
break up any remaining tissue pellets. 
Polymerase Chain Reaction The polymerase chain reaction (PCR) was 
used to amplify ras DNA sequences around the 12th, 13th, and 61st codons 
of N-, H-, and K-ras genes using primers with the same sequences as those 
supplied in kit form by. Clontech Laboratories Inc., Palo Alto, CA. We used 
100 J.ll reactions contammg 10 J.ll of sample DNA m 50 mM KCl, 10 mM 
Tris-Cl (pH 9.0), 1.5 mM MgCl2 , 1 % Triton X-I00, 20 pM of each primer, 
5 U ofTaq polymerase (Promega Corp., Madison, WI), and 0.2 mM of each 
deoxynuclcoside triphosphate. Reactions were run for 40 cycles on a Ther-
mal Cycler (Perkin-Elmer/Cetus), denaturing at 94°C for 1.5 min, anneal-
ing at 55°C for 1.5 min, and extending at 72°C for 1 min. The 100 base pair 
products were identified on a 2% agarose gel and then transferred to nylon 
membranes for Southern hybridization with 32P-labeled wild type ras probes 
using the same protocol as the dot blot hybridizations. 
Dot Blot Hybridizations For hybridizations, we used a modification of a 
previously published method [24]. The PCR products were randomly as-
signed to positions on a dot blot apparatus, 1 J.lI blotted onto nylon mem-
branes, denatured in 0.5 M NaOH, 1 M NaCI for 5 min, neutralized in 1 M 
Tris, 1 M NaCI for 5 min, and immobilized on the membranes with a 
Stratagene UV Stratalinker 1800. The membranes were pre hybridized for 
1 h at 37°C in a hybridization mix containing 5 X SSPE (7.5 mM NaCl, 
0.5 mM NaH2P04, 0.5 mMEDTA-Na2 at pH 7.4), 5 X Denhardt's, 0.1 M 
Na4P20 7 (pH 7.5) and 0.5% sodium dodecylsulfate (SDS). They were then 
incubated for 18 h at 37°C in 10 ml of hybridization mix containing 32p 
labeled oligodeoxynucleotide probe with a specific activity of 105 cpm/ml. 
The probes corresponded to each of the single base pair ras mutations known 
to arise spontaneously in human tumors at the 12th, 13th, and 61st codons of 
N-, H-, and K-ras genes (Clontech Laboratories Inc., Palo Alto, CAl. The 
next morning, the blots were washed twice at room temperature in 6 X SSC 
(0.9 M NaCl, 90 mM sodium citrate at pH 7.0) for 10 min each, and then 
twice in 3 M tetramethylammonium chloride, 50 mM Tris (pH 8), 2 mM 
EDT A, and 0.1 % SDS initially at room temperature for 10 min and finally at 
61°C for approximately 40 min and exposed to x-ray film at -70°C using 
intensifying screens. 
A mutation was identified when a tumor had a hybridization signal that 
was significantly stronger than the background activity and in most cases 
stronger than the positive control signals (well HI0 on all blots in Fig 1) 
with the mutant probes. This technique has enabled us to detect single base 
pair mutations in ras genes (Fig 1). 
Cloning and Sequencing the peR Products The results from dot blot 
hybridizations were confirmed by subcloning PCR products into the pCR 
1000 plasmid. Two cases were selected for subcloning. One contained wild 
type ras sequences by dot blots and the other contained a mutation coding for 
lysine at the 61st codon of N-ras. Both cases were Clark's level IV nodular 
melanomas (Breslow thickness 0.71 and 0.80 mm, respectively). The PCR 
products from both cases were ligated into the pCR 1000 plasmid. Ligation 
products were transfected into INVaF' Eschericllia Coli and grown on L-2 
media containing kanamycin and X-Gal (S-bromo-4-chloro-3-indolyl-P-
D-galactoside) using the manufacturer's protocl (TA Cloning System, Invi-
trogen Corp., San Diego, CAl. Bacterial colonies lacking a functional p-ga-
lactosidase gene and assumed to contain plasm ids with inserts were selected, 
mini preparations of plasmid DNA were made using the alkaline lysis 
method [25], and the inserts in these plasmids were sequenced by the dideoxy 
chain termination method using Sequenase and 3sS-labeled dATP (Sequen-
ase Kit from United States Biochemicals, Cleveland, OH). 
RESULTS 
Ras gene point mutations were identified by mismatch hybridiza-
tion in 36 of the 100 melanomas studied. All specimens contained 
some wild type DNA (top left and right panels, Fig 1). None of the 
levell and 19% of the level II melanomas contained ras mutations. 
This was significantly less than the 45% of level III and more ad-
vanced primary tumors (Table It Chi squared test: p < 0.05). The 
melanomas with ras mutations had a median Breslow thickness of 
0 .72 mm (range: 0.32-6.0 mm), which is significantly thicker 
than the 0.42 mm median thickness (range: 0.10-9.1 mm) of mel-
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Figure 1. Human melanomas contain mutations at N-rns codons 61 and 13 
as detected by mismatch hybridization. This figure shows autoradiographs 
of dot blots probed for mutant and wild type sequences around the 61 st and 
13th codons of N-ras from 92 of the 100 melanomas studied. All wells except 
H9 through H12 contained amplified DNA from the 92 melanomas. The 
position of each melanoma tumor DNA was noted by the alpha-numeric 
coordinates. For example, an N-rns 61 mutation is located in well A4 of the 
proline (PRO) autoradiograph. A mutation was identified when an individ-
ual rumor had a hybridization signal significantly stronger than the back-
ground activity with an individual mutant probe. The top left and top right 
blots were hybridized with wild type probes that code for glutamine at the 
61st codon and glycine at the 13th codon respectively. The remaining blots 
were hybridized with probes containing single base pair mutations at the 
61st codon of N-rns in the left hand column, and the 13th codon of N-ras in 
the right hand column. Wells H9 and Hll contained wild type controls 
consisting of human placental DNA amplified around the 61st and 13th 
codons of N-ras respectively in the left hand column and vice versa in the 
right hand column. H10 contained a positive control for the probe used on 
each blot. H12 contained a negative control consisting of PCR reaction 
mixes without a DNA template. 
anomas without mutations (Mann Whitney U test: p = 0.042). A 
single ras mutation was found in 13 of 28 recurrent and metastatic 
tumors whereas one metastasis had N-ras codon 13 and K-ras codon 
12 mutations. 
Ras mutations were found more than two times more frequently 
in primary tumors from continuously exposed skin (56%) than 
tumors from intermittently or non-sun exposed sites (21 %) (Table 
II). Two patients with acral lentiginous melanomas of the hand 
contained ras point mutations. However, none of the six ill situ 
melanomas from continuously or intermittently exposed body sites 
contained mutated ras. 
The study included primary melanomas and their subsequent 
metastases from 10 patients (Table III). In these cases, there was no 
correlation between the ras mutations found in primary and meta-
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Table I. Correlation Between Ras Oncogene Mutations and Clark's Anatomic Level of Invasion in Melanoma Tumors 
Clark's Level 
II III IV V Mucosal" Recb Met' Total 
nJ 6 21 15 23 4 2 12 17 100 
N61 0 3 6 6 2 0 4 4 25 
N12 0 0 0 0 0 0 0 1 1 
N13 0 0 1 1 0 0 0 1 3 
H61 0 1 0 1 0 0 1 0 3 
H12 0 0 0 0 0 0 0 0 0 
H13 0 0 0 0 0 0 0 0 0 
K61 0 0 1 0 0 0 1 0 2 
K12 0 0 0 0 0 0 0 2' 2 
K13 0 0 0 1 0 0 0 0 1 
Total! 0 4 8 9 2 0 6 8 37 
Percentg 0 19 53 39 50 0 50 47 37 
• Two primary tumors were obtained from mucosa and Clark's level could not be detennined. 
b Locally recnrrent melanoma. 
I Metastic melanoma. 
J The number of melanomas at each stage of progression. 
lOne of the metastases also contained a mutation in N-ras 13. 
f Total number of ras mutations found. 
l (Number of ras mutations found/number of tumors studied) X 100. 
static tumors. In two cases, ras mutations occurred in primary 
tumors but not their subsequent metastases. Mutations were identi-
fied in five metastatic melanomas but not the original primary 
tumors. One metastatic melanoma contained two separate muta-
tions with arginine replacing glycine at the 12th codon of K-ras and 
the 13th codon of N-ras. In one patient, different ras mutations were 
present in the primary tumor (aspartate at the 13th codon of K-ras) 
and the metastasis (arginine at the 12th codon of K-ras). 
Twenty-five (68%) of the 37 ras point mutations in the 36 mela-
nomas occurred at the 61st codon of N-ras (Table IV) . Mutations 
were significantly more common at this codon compared with any 
other examined (Chi squared test: p < 0.005). The most frequent 
mutation at all the codons examined was to a mutant arginine 
(Table IV; 15 cases, 41 %; Chi squared test, p < 0.005). Mutations 
that introduced a positively charged amino acid (such as arginine, 
lysine, or histidine) into the GTP binding domain represented 27 of 
the 37 mutations (73%), and were significantly more common than 
mutations that introduced a neutral or negatively charged residue, 
such as leucine or aspartate, respectively (Chi squared test: p < 
0.01). 
The most common single base mutation was aT· A to C . G 
transition in 10 cases, followed by a G . C to C . G transversion in 
eight cases (Table IV). However, the series included examples of 
each of the possible single base mutations, with C . G to T . A 
transitions occurring least frequently in only two cases. No single 
base mutation was significantly more common than any other. 
However, all the mutations occurred in or immediately adjacent to 
potential pyrimidine dimers . The nucleotide sequences of the sub-
cloned PCR products from two melanomas confirmed the findings 
with dot blot hybridizations (Fig 2). 
DISCUSSION 
This study found ras mutations in 36% of melanomas and signifi-
cantly more often in biologically advanced tumors. We looked for 
all the possible activating ras mutations that are known to occur by 
Table II. Correlation Between Ras Oncogene Mutations, Clinicopathologic Features, and Sun Exposure in Primary Melanoma Tumors 
Tumor Type and Exposure to the Sun" 
Melanoma In Situ Superficial Spreading 
c ns c ns 
n' 2 3 0 15 34 1 
N61 0 0 0 5 6 0 
N12 0 0 0 0 0 0 
N13 0 0 0 2 0 0 
H61 0 0 0 1 1 0 
H12 0 0 0 0 0 0 
H13 0 0 0 0 0 0 
K61 0 0 0 0 1 0 
K12 0 0 0 0 0 0 
K13 0 0 0 1 0 0 
Totals 0 0 0 9 8 0 
Percenth 0 0 0 60 24 0 
• Body sites either continuously (c), intermittently (i), or non -sun e"posed (ns). 
b Lentigo maligna. 
c 
5 
3 
0 
0 
0 
0 
0 
0 
0 
0 
3 
60 
' Two patients with acrallentiginous melanoma of the hand were studied. 
'Two primary melanomas were obtained from mucosa and depth could not be detennined. 
, Number of melanoma tumors. 
Nodular 
3 
1 
0 
0 
0 
0 
0 
0 
0 
0 
1 
33 
f Anatomical locations of one nodular and two superficial spreading melanomas were not specified. 
t Total number of ras mutations found . 
, (Number of ras mutations found/number of tumors studied) X 100. 
ns 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
LMb AU MucosalJ Total 
c C ns 
1 2 2 68 (71)1 
0 2 0 17 
0 0 0 0 
0 0 0 2 
0 0 0 2 
0 0 0 0 
0 0 0 0 
0 0 0 1 
0 0 0 0 
0 0 0 1 
0 2 0 23 
0 100 0 32 
288 BALL ET AL 
Table III. Ras Oncogene Mutations in Primary and Metastatic 
Melanoma Tumors 
Primary: 
Location/ Primary Metastatis 
Patient Sun/Level' (wt/mut)b (wt/mut) 
1 Back/i/III ND' ND 
2 Leg/i/IV ND ND 
3 Back/i/IV ND N61 (gln/arg) 
4 Back/i/V ND N61 (gln/his1) 
5 NaJ/na/IV ND N61 (gln/lys) 
6 Mucosal/ns/na ND N12 (gly/asp) 
N13 (gly/arg) 
7 Chest/i/ll ND K12 (gly/arg) 
8 Neck/c/IV K13 (gly/asp) K12 (gly/arg) 
9 Hand/c/IV N61 (gln/glu) ND 
10 Back/i/V N61 (gln/his2) ND 
• Location of tumor/continuously (c), intermittently (i), or non-sun exposed (ns)/ 
Clark's level. 
I Wild rype amino acid/amino acid associated with ras condon mutation. 
, NO, no mutations detected. 
J Data not available. 
single base pair mutations in the three human ras genes [15]. Our 
results show that activating ras mutations are not required for mela-
noma initiation because they were not found in the six level I mela-
nomas. Most of the mutations occur during the progression from 
Clark's level II to III primary melanomas. This is the stage of pro-
gression associated with the start of the vertical growth phase and 
more aggressive behavior [2] . 
Transfection of oncogenic ras into a number of different cultured 
cell types causes many phenotypic changes seen in vertical growth 
phase melanomas such as epithelioid cell type [10], increased pro-
tease production [26,27], and increased cell motility [28]. We think 
that these changes are important in the progression of melanomas 
and a~e related to ras activation. Our hypothesis that activated ras 
contrIbutes to the growth advantage of melanomas in the vertical 
growth phase of dermal invasion is supported by these cell culture 
experiments [10,26-28]. 
However, ras mutations are not required to produce melanoma 
Table IV. Ras Gene Mutations Detected in Primary and 
Metastatic Melanomas 
Wild Type/ Mutation/ 
n' Amino Acidb Amino Acid' 
N61 J 8 CAA/Gln 
N61 3 CAA/Gln 
N61 3 CAA/Gln 
N61 4 CAA/Gln 
N61 3 CAA/Gln 
N61 3 CAA/Gln 
N61 1 CAA/Gln 
N12 1 GGT/Gly 
N13 3 GGT/Gly 
H61 1 CAG/Gln 
H61 1 CAG/Gln 
H61 1 CAG/Gln 
K61 1 CAA/Gln 
K61 1 CAA/Gln 
K12 2 GGT/Gly 
K13 1 GGT/Gly 
Total 37 
• The number of mutations found. 
I The wild rype nucleotide sequence and corresponding amino acid. 
, The mutant nucleotide sequence and corresponding amino acid. 
J Ras gene codon. 
CGA/Arg 
CAT/His1 
CAD/His2 
AAA/Lys 
CTA/Leu 
CAG/Glu 
CCA/Pro 
GAT/Asp 
CGT/Arg 
CAT/His 1 
CTG/Leu 
CGG/Arg 
CGT/Arg 
CAC/His2 
CGT/Arg 
GAC/Asp 
-
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Figure 2. Sequencing gel autoradiograph representing a wild type and G to 
T transversion mutation of N-ras 61. Anti-sense N-ras sequences of two 
melanomas are shown. One tumor contains the wild type anti-sense 61 st 
codon TTG (designated by -) which codes for glutamine. The other 
melanoma contains the antisense codon for a lysine mutation (TTT, desig-
nated hy -+) representing a G to T base substitution at the 61st codon. 
metastasis. Ras mutations were no more frequent in metastatic than 
level III melanomas and, in one patient, different mutations were 
found in primary and metastatic tumors. The comparable frequency 
of ras mutations in Clark's level III and more advanced melanomas 
cannot be solely related to increased genetic instability of these 
tumors [21,29]. If ras mutations were a marker of increased genetic 
instability of advanced melanomas, ras mutations would be more 
frequent in the most biologically advanced metastatic tumors, 
which was not the ca~e in this study. Additionally, although ras 
genes may be deleted m some advanced tumors, a deletion in the 
short arm of choromsome 1 where N-ras is located is not a charac-
teristic of melanoma [29]. 
We used a very sensitive technique for detecting ras gene muta-
tions [15,30]. In all cases, at least 10% of the biopsied material was 
estimated to be ~elan~ma, wh.ich exceeds the 2% sensitivity previ-
ously reRorted wI~h thiS techmque J15]. This leaves the most likely 
explanation for different ras mutations in some primary and meta-
static melanomas from the same patients as the polyclonal nature of 
advanced malign~ncie~ [31-34] . Malignancies appear to start as 
monoclonal proltferatlons that develop subclones with growth 
advantages as they progress [10,12,31 - 33]. Ras mutation may 
offer a growth advantage to locally progressing melanomas that 
is not required in metastatic lesions. Therefore, the clone from 
the primary tumor that produces a metastasis may not be the one 
containing a ras mutation. Other studies support this theory of 
selection of sequential mutations in advancing malignancies 
[12,29,31,34]. 
Ras mutations were identified more frequently than the 5 to 25% 
reported in previous series [14,15,20,22]. The reason for this is not 
apparent, but may reflect the larger number of melanomas in this 
study compared to previous ones [14 - 18,20,22]. Most of these 
earlier studies did not specify the thickness of primary tumors 
[14-18,20] nor whether they were from sun-exposed skin 
[15 -18,20,22] . Another possibility for our results is false-positive 
single base substitution due to random Taq polymerase error caus-
ing the insertion of the incorrect nucleotide. Our experiments were 
performed to minimize Taq polymerase error. Specifically, we used 
the smallest number of cycles (40 cycles) to obtain adequate 
amounts of DNA, the deoxynucleotides were added in equal con-
centrations, the reaction times were kept as short as possible, and the 
MgCl2 concentration was as low as possible to support DNA syn-
thesis. If Taq polymerase error did occur at a rate of 1/50,000 
nucleotides synthesized per cycle, following 40 cycles, one error 
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er 2,500 nucleotides can be expected [35]. This error rate is 
fow enough to expect few false-positive base substitutions occur-
ring in our PCR reactions. No Taq polymerase error was detected in 
the melanoma wild type blots (Fig 1) nor in the human placental 
DNA positive controls. Furthermore, DNA sequencing confirmed 
the results of the mismatch hybridization experiments for two 
tumors . 
We only found ras mutations in the melanomas from continu-
ously or intermittently sun-exposed skin. This supports Van T' 
Veer et a/'s hypothesis that UVR produces ras mutations in this 
subset of melanomas [14]. Additionally, most of the mutations were 
in the 61st codon of N-ras, the most frequent site of ras mutations in 
previous studies of melanoma [14,15,18,20]. This is also a preferred 
site for UVR-induced ras mutations in cultured cells [9] and cluo-
matid recombination in advanced melanomas [19]. 
In this study, all the ras mutations occurred in codons containing 
potential pyrimidine din~er~ . yv~ prod.uces point mutations by 
forming cyclobutane pynmld1l1e dlmers 111 shuttle vectors [36,37] 
and the ras genes of animal models for mutagenesis [8]. They are 
usually C . G to T . A transitions in TC pairs [36,37]. However, 
this is the least common activating ras mutation in this and other 
series of melanomas [15 -18,20] where T . A to C . G transitions in 
TT pairs predominate [15,20]. There are three possible explanations 
for this dichotomy: 1) UVR produces different mutations ill vitro 
and in vivo; 2) UVR did not produce the ras mutations we observed; 
and/or 3) there was phenotypic selection of the less frequent UVR 
induced mutations. The first hypothesis is unlikely because a C . G 
to T . A transition is the most frequent mutation in p53 genes from 
cutaneous squamous cell carcinomas in sun damaged skin [7]. Al-
though shuttle vector experiments [36,37] have used high doses of 
non-physiologic UVC radiation [5], epidemiologic [3-5] and ex-
perimental evidence [6] suggests that UVR plays a causal role in 
melanoma and, due to an error in DNA repair, can lead to point 
mutations in ras genes [8,9] . We hypothesize that phenotypic selec-
tion favors the less common UVR induced mutations. The C . G to 
T . A transitions in potential pyrimidine dimers found in shuttle 
vectors [36,37] cannot occur at the 61st codon of human N- and 
K-ras genes [18] and would produce a stop codon at the 61st codon 
of H-ras . In fact, the majority of these mutations produced stop 
co dons in shuttle vectors [37]. Mutations that create new stop 
codons in ras would probably not produce a phenotypic advantage 
in a developing melanoma. On the other hand, all missense muta-
tions in the 61st codon of N-ras reduce GTPase activity by 90%. 
They disrupt the hydrogen bond between the side chain of gluta-
mine-61 and y phosphate of GTP in the normally stable transi-
tion complex [38]. This leads to increased activity of p21"" in cel-
lular signal-transduction pathways [13]. Although all missense 
mutations produce this change [38), they have different trans-
forming abilities [39]. The majority of ras mutations in this and 
previous studies produced activating mutations that coded for 
amino acids with positively charged side chains [14-16,18,20]. It is 
possible that these substitutions may be different in the way they 
alter the charge density around the y phosphate or disrupt the inter-
action between the GTP binding domain the GTPase activator pro-
teins or effector molecules [38]. This could be biologically impor-
tant and explain why this type of mutation is most frequent in 
melanomas. 
We have demonstrated that ras mutations occur in a subset of 
advanced melanomas from sun-exposed skin. These mutations 
are linked to melanoma progression from level II to III tumors but 
not initiation. They are probably a small part of the aggregate dam-
age to many oncogenes and anti-oncogenes during tumor progres-
sion [11,12]. Activated ras may be responsible for some of the fea-
tures of advanced melanomas by giving them a growth advantage 
during their vertical growth phase of progression [10,26-28] and 
also contributing to chemotherapy resistance [40] . Identifying 
melanomas with activated ras may become more important as 
therapies aimed at reversing the changes produced by ras are devel-
oped [41]. 
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